ISIS 113715

Drug Profile

ISIS 113715

Latest Information Update: 05 Apr 2011

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Class Antisense oligoribonucleotides
  • Mechanism of Action Protein tyrosine phosphatase non receptor type 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 01 Mar 2011 Discontinued - Phase-II for Type-2 diabetes mellitus in Russia (SC)
  • 01 Mar 2011 Discontinued - Phase-II for Type-2 diabetes mellitus in Poland (SC)
  • 29 Jun 2010 Efficacy data from a phase II trial in Type-2 diabetes mellitus (NCT00455598) presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top